Sarepta Therapeutics· @Sarepta · X·· 2025-11-25AI 评分40
AI 导读
我们刚刚宣布，美国FDA已批准在ENDEAVOR研究的第8队列中开始给药，以评估在针对非行走患者的基因治疗中采用强化免疫抑制方案。阅读新闻稿：https://bit.ly/3Kkhw22
正文
We just announced that the U.S. FDA approved to begin dosing in Cohort 8 of the ENDEAVOR study to evaluate the use of an enhanced immunosuppressive regimen as part of treatment with our gene therapy for non-ambulatory patients. Read the press release: https://bit.ly/3Kkhw22
来源：Sarepta Therapeutics · x.com